Physician

Olusola Ogundipe, M.D.

According to 2025 Medicare claims, Olusola Ogundipe, M.D. (NPI: 1194849901) practices hematology/oncology in the Michigan City-La Porte, IN market, with the plurality of this provider's patient population coming from La Porte, IN. This provider's primary affiliated billing organization is NORTHWEST CANCER CENTERS, PC (NPI: 1578527826; TIN: 30-0200047) and primary practice location at 46360-7842. Ogundipe is affiliated with the Powers Health Partners ACO (ACO ID: A3632), participating under the MSSP model.

Ogundipe's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 392 traditional Medicare patients, billed 151,166 HCPCS/CPT codes, and received $2,367,434 in Medicare payments. The top billing code was 36415 (Insertion of needle into vein for collection of blood sample). Part D data shows 1,304 prescription claims across 181 beneficiaries totaling $5,555,689 in drug costs, led by Jakafi (Ruxolitinib Phosphate). 2020 DME data shows 87 claims. Open Payments data shows 201 records totaling $5,812. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $319,576 to $2,367,434. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $1,072,714 to $5,555,689. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $4,902 to $1,631.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	561	29,257	$319,576
2016	537	16,193	$244,815
2017	528	16,781	$279,938
2018	503	12,986	$166,880
2019	679	93,804	$542,867
2020	635	133,412	$1,105,281
2021	363	138,191	$2,539,436
2022	349	146,112	$2,017,988
2023	363	106,402	$1,715,967
2024	392	151,166	$2,367,434

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	164	1,118	$1,072,714
2016	173	1,215	$1,483,596
2017	220	1,412	$1,499,986
2018	200	1,410	$1,963,302
2019	236	1,553	$2,830,142
2020	247	1,599	$3,743,090
2021	173	981	$3,750,147
2022	133	737	$4,380,250
2023	129	739	$4,605,161
2024	181	1,304	$5,555,689

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	49	$3,765
2016	N/R	42	$20,360
2017	N/R	34	$9,463
2018	N/R	70	$8,458
2019	N/R	133	$13,268
2020	N/R	87	$6,032
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
36415	Insertion of needle into vein for collection of blood sample	232	1,291	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	230	1,259	$8
82310	Calcium level, total	226	1,224	$5
82247	Bilirubin level, total	226	1,224	$5
82040	Albumin (protein) level	226	1,223	$5

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jakafi	Ruxolitinib Phosphate	96	2,880	$1,668,918
Imbruvica	Ibrutinib	44	1,232	$664,009
Ojjaara	Momelotinib Dihydrochloride	21	630	$580,840
Givlaari	Givosiran Sodium	11	330	$452,416
Tagrisso	Osimertinib Mesylate	16	480	$266,072

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	201	$5,812	Daiichi Sankyo Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Olusola Ogundipe, M.D.?

Tedicare shows public-source Medicare data for Olusola Ogundipe, M.D. (NPI 1194849901), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Olusola Ogundipe, M.D. have ACO affiliation data?

Olusola Ogundipe, M.D. is shown with ACO affiliation data for Powers Health Partners ACO (MSSP, ACO ID A3632).

What billing organization is linked to Olusola Ogundipe, M.D.?

Olusola Ogundipe, M.D. is linked to NORTHWEST CANCER CENTERS, PC (billing NPI 1578527826) in the available physician profile data.

Does Olusola Ogundipe, M.D. have Open Payments data?

Olusola Ogundipe, M.D. has 201 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.